SHIELD THERAPEUTICS ORD 1.5P overview

Hardman & Co Research Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team 15-Nov-2023 / 07:30 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since...

Hardman & Co Research Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering 25-Jul-2023 / 09:45 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has...

Hardman & Co Research Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptions 17-May-2023 / 07:15 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptions Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in...

Hardman & Co Research Hardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital 23-Jan-2023 / 11:15 GMT/BST Analyst interview | Life Sciences Q&A on Shield Therapeutics (STX) | Positioned for profitability with Viatris deal and its additional capitaltive Shield Therapeutics (STX) is the topic of conversation when Dr Martin Hall joins DirectorsTalk Interviews. Martin summarises a number of announcements made by the company recently,...

Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX) - Positioned for growth and profitability 13-Jan-2023 / 07:15 GMT/BST Hardman & Co Research on Shield Therapeutics (STX): Positioned for growth and profitability Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has been increasing physician awareness of the...

Hardman & Co Research Hardman & Co Research on Shield Therapeutics (STX): Accrufer momentum building 15-Sep-2022 / 13:52 GMT/BST Hardman & Co Research on Shield Therapeutics (STX): Accrufer momentum building Shield Therapeutics (Shield) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Following launch of Accrufer® in the US, in July 2021, the initial challenge was to greatly improve...

Hardman & Co Research Hardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous 12-Aug-2022 / 11:45 GMT/BST Hardman & Co Video | Analyst interview Shield Therapeutics (STX): Upside potential is enormous Shield Therapeutics (STX) is the topic of conversation when Martin Hall joins DirectorsTalk Interviews. Despite launching a drug into the US market, Shield has performed really badly over the past 12 months, Martin explains what happened, shares his thoughts on the considerable...

Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX): Looking to accelerate positive signals in the US 26-Jul-2022 / 07:15 GMT/BST Hardman & Co Research on Shield Therapeutics (STX): Looking to accelerate positive signals in the US Shield Therapeutics (Shield) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Following launch of Accrufer® in the US in July 2021, the...